Filing Details
- Accession Number:
- 0001104659-15-074204
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-10-29 18:14:01
- Reporting Period:
- 2015-10-27
- Filing Date:
- 2015-10-29
- Accepted Time:
- 2015-10-29 18:14:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1592288 | Dimension Therapeutics Inc. | DMTX | Biological Products, (No Disgnostic Substances) (2836) | 463942159 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1601264 | Michael Dybbs | C/O New Leaf Venture Partners 7 Times Square, Suite 3502 New York NY 10036 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-10-27 | 1,097,745 | $0.00 | 1,097,745 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2015-10-27 | 961,538 | $13.00 | 2,059,283 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Preferred Stock | Disposition | 2015-10-27 | 3,208,711 | $0.00 | 1,097,745 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect |
Footnotes
- The Series B Preferred Stock automatically converted into Common Stock, for no additional consideration, on a 2.923-for-1 basis at the closing of the Issuer's initial public offering, and had no expiration date.
- These securities are held by New Leaf Ventures III, L.P. ("NLV-III") and New Leaf Growth Fund I, L.P. ("NLGF"). New Leaf Venture Associates III, L.P. ("NLVA-III") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III") is the general partner of NLVA-III. New Leaf Growth Associates I, L.P. ("NLGA") is the general partner of NLGF and NLVM-III is the general partner of NLGA. Reporting Person is employed by New Leaf Venture Partners, L.L.C., which is affiliated with the above entities and disclaims beneficial ownership of the shares held by NLV-III and NLGF except to the extent of his pecuniary interests therein if any.